As a global leader in in vitro diagnostics, Roche Diagnostics is committed to the development and delivery of medical testing products and services from the prevention, early detection, diagnosis, treatment monitoring and prognosis of disease. In 1999, Malaysian overseas Chinese Mr. Huang Baixing came to China and was appointed General Manager of Roche Diagnostics Greater China in 2006. It can be said that he witnessed the entire development of Roche Diagnostics in China and witnessed the start, growth and development of in vitro diagnostics in China.
Observing the Chinese diagnostic market
The so-called in vitro diagnosis refers to objective information about health and disease obtained by detecting blood and other samples of patients (such as urine and tissue cells). This test can be performed in the laboratory or at the bedside. The in vitro diagnostic industry has been developed with the development of modern laboratory medicine, which in turn has led to the rapid development of disciplines such as laboratory medicine and basic medicine. At present, 70% of global medical decision-making is based on in vitro diagnostic information. It is predicted that by 2015, China's in vitro diagnostic market will exceed 30 billion yuan, becoming the world's third largest market.
Roche Diagnostics' performance in China is even more impressive. By the end of 2013, the company has achieved a 30% growth for three consecutive years. It cannot be said that the achievement of these achievements is largely due to the fact that Mr. Huang Baixing, the head of Roche Diagnostics China, who has been deeply involved in China for 13 years. Based on his profound understanding and understanding of the Chinese market, on the basis of combining market demand and based on the principle of patient benefit, he has formulated the development strategy that best suits the Chinese market.
Huang Boxing told reporters that from 2000, Roche diagnosed China's establishment in Shanghai Waigaoqiao Free Trade Zone, and the company has gone through 15 years. In the course of this 15 years of development. Roche Diagnostics China started from scratch, and achieved nearly 7 billion RMB in business volume in 2014. It is worth mentioning that in order to meet the demand for high quality diagnostic products from home and abroad, Roche Diagnostics launched the largest investment in the Chinese market in November 2014: 250 million Swiss francs (about 2.5 billion yuan) in the next three years. ) Established the 8th largest production base of Roche Diagnostics in Suzhou Industrial Park. It is reported that the base will break through the way of building China in China, and more is built in China to serve the world.
In addition to the rapid growth of business volume, Roche Diagnostics China's employees have grown from less than 100 people to more than 1,800, and new recruits are growing at a rate of 20% per year. At the same time, the company's turnover rate is only about 7%. Especially in the past few years, Roche Diagnostics China has been awarded the “China Outstanding Employer†certification by the joint investigation agency CRF for five consecutive years. In the words of Huang Baixing, looking back on the 15 years of development, it can be seen that Roche diagnosed China on the right path.
Inulin,Ganoderma lucidum extract,Senna leaf powder
Fufeng Sinuote Biotechnology Co.,Ltd. , https://www.sinuotebio.com